Resveratrol inhibits the phosphatidylinositide 3-kinase/protein kinase B/mammalian target of rapamycin signaling pathway in the human chronic myeloid leukemia K562 cell line

Oncology Letters

Volumn 7, Issue 6, 2014, Pages 2093-2098

  Sui, Tao ^a   Ma, Li ^a   Bai, Xue ^a   Li, Qing ^a   Xu, Xinnv ^a  

^a TIANJIN FIRST CENTRAL HOSPITAL   (China)

Author keywords

Chronic myeloid leukemia; Mammalian target of rapamycin; Phosphatidylinositide 3 kinase; Protein kinase B; Resveratrol

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; CYCLIN D1; INITIATION FACTOR 4E BINDING PROTEIN 1; MAMMALIAN TARGET OF RAPAMYCIN; P70S6 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOTRANSFERASE; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; RAPAMYCIN; RESVERATROL; SH 6; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOTOXICITY; DOWN REGULATION; HUMAN; HUMAN CELL; PHOSPHORYLATION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; WESTERN BLOTTING;

EID: 84898904558     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2014     Document Type: Article

References (46)

1. Chandra HS, Heisterkamp NC, Hungerford A, Morrissette JJ, Nowell PC, Rowley JD and Testa JR: Philadelphia Chromosome Symposium: commemoration of the 50th anniversary of the discovery of the Ph chromosome. Cancer Genet 204: 171-179, 2011.
2. Deininger MW, Goldman JM and Melo JV: The molecular biology of chronic myeloid leukemia. Blood 96: 3343-3356, 2000.
3. Hantschel O and Superti-Furga G: Regulation of the c-Abl and Bcr-Abl tyrosine kinases. Nat Rev Mol Cell Biol 5: 33-44, 2004.
4. Sattler M and Griffin JD: Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol 40 (Suppl 2): S4-S10, 2003.
5. Barrett D, Brown VI, Grupp SA and Teachey DT: Targeting the PI3K/AKT/mTOR signaling axis in children with hematologic malignancies. Paediatr Drugs 14: 299-316, 2012.
6. Horita M, Andreu EJ, Benito A, Arbona C, Sanz C, Benet I, et al: Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL. J Exp Med 191: 977-984, 2000.
7. Pene-Dumitrescu T and Smithgall TE: Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem 285: 21446-21457, 2010.
8. Baum KJ and Ren R: Effect of Ras inhibition in hematopoiesis and BCR/ABL leukemogenesis. J Hematol Oncol 1: 5, 2008.
9. Notari M, Neviani P, Santhanam R, Blaser BW, Chang JS, Galietta A, et al: A MAPK/HNRPK pathway controls BCR/ABL oncogenic potential by regulating MYC mRNA translation. Blood 107: 2507-2516, 2006.
10. Baran Y and Saydam G: Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia. J Blood Med 3: 139-150, 2012.
11. Mauro MJ and Deininger MW: Chronic myeloid leukemia in 2006: a perspective. Haematologica 91: 152, 2006.
12. Shah NP and Sawyers CL: Mechanisms of resistance to STI571 in Philadelphia chromosome-associated leukemias. Oncogene 22: 7389-7395, 2003.
13. Sawyers CL, Hochhaus A, Feldman E, Goldman JM, Miller CB, Ottmann OG, et al: Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. Blood 99: 3530-3539, 2002.
14. Soleas GJ, Diamandis EP and Goldberg DM: Resveratrol: a molecule whose time has come? And gone? Clin Biochem 30: 91-113, 1997.
15. Jang DS, Kang BS, Ryu SY, Chang IM, Min KR and Kim Y: Inhibitory effects of resveratrol analogs on unopsonized zymosan-induced oxygen radical production. Biochem Pharmacol 57: 705-712, 1999.
16. Inoue H, Jiang XF, Katayama T, Osada S, Umesono K and Namura S: Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci Lett 352: 203-206, 2003.
17. Yu W, Fu YC and Wang W: Cellular and molecular effects of resveratrol in health and disease. J Cell Biochem 113: 752-759, 2012.
18. Delmas D, Solary E and Latruffe N: Resveratrol, a phytochemical inducer of multiple cell death pathways: apoptosis, autophagy and mitotic catastrophe. Curr Med Chem 18: 1100-1121, 2011.
19. Tinhofer I, Bernhard D, Senfter M, Anether G, Loeffler M, Kroemer G, et al: Resveratrol, a tumor-suppressive compound from grapes, induces apoptosis via a novel mitochondrial pathway controlled by Bcl-2. FASEB J 15: 1613-1615, 2001.
20. Mgbonyebi OP, Russo J and Russo IH: Antiproliferative effect of synthetic resveratrol on human breast epithelial cells. Int J Oncol 12: 865-869, 1998.
21. Ahmad N, Adhami VM, Afaq F, Feyes DK and Mukhtar H: Resveratrol causes WAF-1/p21-mediated G(1)-phase arrest of cell cycle and induction of apoptosis in human epidermoid carcinoma A431 cells. Clin Cancer Res 7: 1466-1473, 2001.
22. Dörrie J, Gerauer H, Wachter Y and Zunino SJ: Resveratrol induces extensive apoptosis by depolarizing mitochondrial membranes and activating caspase-9 in acute lymphoblastic leukemia cells. Cancer Res 61: 4731-4739, 2001.
23. Benitez DA, Pozo-Guisado E, Alvarez-Barrientos A, Fernandez-Salguero PM and Castellón EA: Mechanisms involved in resveratrol-induced apoptosis and cell cycle arrest in prostate cancer-derived cell lines. J Androl 28: 282-293, 2007.
24. Fulda S and Debatin KM: Resveratrol-mediated sensitisation to TRAIL-induced apoptosis depends on death receptor and mitochondrial signalling. Eur J Cancer 41: 786-798, 2005.
25. Shankar S, Siddiqui I and Srivastava RK: Molecular mechanisms of resveratrol (3,4,5-trihydroxy-trans-stilbene) and its interaction with TNF-related apoptosis inducing ligand (TRAIL) in androgen-insensitive prostate cancer cells. Mol Cell Biochem 304: 273-285, 2007.
26. Shankar S, Singh G and Srivastava RK: Chemoprevention by resveratrol: molecular mechanisms and therapeutic potential. Front Biosci 12: 4839-4854, 2007.
27. Jiang H, Zhang L, Kuo J, Kuo K, Gautam SC, Croc L, et al: Resveratrol-induced apoptotic death in human U251 glioma cells. Mol Cancer Ther 4: 554-561, 2005.
28. Jiang H, Shang X, Wu H, Gautam SC, Al-Holou S, Li C, et al: Resveratrol downregulates PI3K/Akt/mTOR signaling pathways in human U251 glioma cells. J Exp Ther Oncol 8: 25-33, 2009.
29. Yang CS, Landau JM, Huang MT and Newmark HL: Inhibition of carcinogenesis by dietary polyphenolic compounds. Annu Rev Nutr 21: 381-406, 2001.
30. Quoc Trung L, Espinoza JL, Takami A and Nakao S: Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition. PLoS One 8: e55183, 2013.
31. Miki H, Uehara N, Kimura A, Sasaki T, Yuri T, Yoshizawa K and Tsubura A: Resveratrol induces apoptosis via ROS-triggered autophagy in human colon cancer cells. Int J Oncol 40: 1020-1028, 2012.
32. Hussain AR, Uddin S, Bu R, Khan OS, Ahmed SO, Ahmed M and Al-Kuraya KS: Resveratrol suppresses constitutive activation of AKT via generation of ROS and induces apoptosis in diffuse large B cell lymphoma cell lines. PLoS One 6: e24703, 2011.
33. Truong M, Cook MR, Pinchot SN, Kunnimalaiyaan M and Chen H: Resveratrol induces Notch2-mediated apoptosis and suppression of neuroendocrine markers in medullary thyroid cancer. Ann Surg Oncol 18: 1506-1511, 2011.
34. Chen Q, Ganapathy S, Singh KP, Shankar S and Srivastava RK: Resveratrol induces growth arrest and apoptosis through activation of FOXO transcription factors in prostate cancer cells. PLoS One 5: e15288, 2010.
35. Leong CW, Wong CH, Lao SC, Leong EC, Lao IF, Law PT, et al: Effect of resveratrol on proliferation and differentiation of embryonic cardiomyoblasts. Biochem Biophys Res Commun 360: 173-180, 2007.
36. Kaminski J, Lançon A, Aires V, Limagne E, Tili E, Michaille JJ and Latruffe N: Resveratrol initiates differentiation of mouse skeletal muscle-derived C2C12 myoblasts. Biochem Pharmacol 84: 1251-1259, 2012.
37. Yu XM, Jaskula-Sztul R, Ahmed K, Harrison AD, Kunnimalaiyaan M and Chen H: Resveratrol induces differentiation markers expression in anaplastic thyroid carcinoma via activation of Notch1 signaling and suppresses cell growth. Mol Cancer Ther 12: 1276-1287, 2013.
38. Yap TA, Garrett MD, Walton MI, Raynaud F, de Bono JS and Workman P: Targeting the PI3K-AKT-mTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 8: 393-412, 2008.
39. Osaki M, Oshimura M and Ito H: PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9: 667-676, 2004.
40. Wetzker R and Rommel C: Phosphoinositide 3-kinases as targets for therapeutic intervention. Curr Pharm Des 10: 1915-1922, 2004.
41. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev 30: 193-204, 2004.
42. Franke TF, Hornik CP, Segev L, Shostak GA and Sugimoto C: PI3K/Akt and apoptosis: size matters. Oncogene 22: 8983-8998, 2003.
43. Morgensztern D and McLeod HL: PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16: 797-803, 2005.
44. Martelli AM, Evangelisti C, Chiarini F, Grimaldi C, Manzoli L and McCubrey JA: Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia. Expert Opin Investig Drugs 18: 1333-1349, 2009.
45. Gao N, Zhang Z, Jiang BH and Shi X: Role of PI3K/AKT/mTOR signaling in the cell cycle progression of human prostate cancer. Biochem Biophys Res Commun 310: 1124-1132, 2003.
46. Sun C, Hu Y, Liu X, Wu T, Wang Y, He W and Wei W: Resveratrol downregulates the constitutional activation of nuclear factor-kappaB in multiple myeloma cells, leading to suppression of proliferation and invasion, arrest of cell cycle, and induction of apoptosis. Cancer Genet Cytogenet 165: 9-19, 2006.